Contact Us
Please contact the Cancer Research Team for more information:
01772 528 475cancerresearchteam@Lthtr.nhs.uk
Last Updated: 2026-04-14 08:09:16
Colorectal
|
Specialty: Colorectal |
PI: Dr Deborah Williamson |
|
CPMS No: 71028 |
Estimated Opening: 19/04/2026 |
|
Description: Colorectal cancer is 37% higher in the North-West than the national average and is treated by chemotherapy, including fluorouracil, capecitabine, and oxaliplatin. A side effect of these drugs is loss of memory, forgetfulness, and general brain fog, which can persist for months after the end of treatment, collectively known as “chemo-brain”. We will use an existing prehabilitation intervention we have developed, which increases fitness and reduces hospital length of stay in colorectal cancer surgery patients, to try and improve chemo-brain symptoms in those undergoing chemotherapy and improve quality of life. The study aims to: Aim 1: To determine if prehabilitation promotes an improvement in brain health in colorectal cancer patients before starting chemotherapy. Aim 2: To determine if prehabilitation protects against cognitive and neural dysfunction, to establish if prehabilitation can reduce the negative effects on the brain following chemotherapy. Aim 3: To determine if brain health changes following prehabilitation lead to improvements in quality of life three months after cessation of chemotherapy in colorectal cancer patients. We will use a range of physiological tests (cardiopulmonary exercise testing, blood panels), neuroscientific (electroencephalography) and psychological (cognitive test battery, well-being questionnaires) to determine if our prehabilitation intervention improves chemo-brain and quality of life in colorectal cancer patients. Our intervention will be delivered across Lancashire, aimed at reducing health inequalities and negative health outcomes associated with cancer treatment in our region. |
|
Multi disease sites and research areas
|
Specialty: Multi disease sites and research areas |
PI: Dr Omi Parikh |
|
CPMS No: 57739 |
Estimated Opening: 01/04/2026 |
|
Description: This is a Phase 1-2 trial which is testing a new drug called ATTR-01 to find out if it may work to treat different types of cancer. Whilst there are already anticancer medicines available, some people are not able to use these, and they do not work for everyone. ATTR-01 is made from a weakened adenovirus (Ad5). An Ad5 is a common human virus that causes cold like symptoms. Normally, an Ad5 will infect many of your cells. ATTR-01 has been developed so that it only infects and only replicates (multiplies itself) in cancer cells. The drug is designed so that it does not kill healthy cells. This should make the drug better at killing cancer and cause fewer drug side effects. ATTR-01 is a type of immunotherapy (it stimulates your immune system) to kill cancer cells. ATTR-01 is injected into a participant’s blood stream. Three doses of the drug are given over one week. Once in the participant's blood, ATTR-01 circulates and infects cancer cells. ATTR-01 can kill cancer cells in two ways: 1. Inside the cancer cell, ATTR-01 forces the cancer cell to make and release a potent (strong) drug. This drug can kill cancer cells by activating participant's immune system to fight the cancer. 2. ATTR-01 kills cancer cells when the virus replicates (it bursts the cancer cell). This study consists of a Master Protocol which provides details of the study as a whole and refers to subprotocols. Subprotocol A is the First in Human (FIH) study of ATTR-01 which will take place first and is Phase 1 dose finding study in participants with select advanced epithelial solid tumours. Once the dose is selected the study can proceed to subprotocol B which is a Phase 2 dose expansion study to check the efficacy of ATTR-01 in participants with select advanced solid tumours. Finally, Subprotocol R is a long-term follow-up study (up to two years) for long term safety and survival of participants from the sub-protocol A and sub-protocol B studies. |
|
Radiotherapy
|
Specialty: Radiotherapy |
PI: - |
|
CPMS No: 56569 |
Estimated Opening: 01/07/2025 |
|
Description: Cancer of the sinuses (the air spaces in our face around the nose) is a rare but devastating disease, which is often aggressive and extensive by the time something is noticed to be wrong. Radiotherapy is an important part of the treatment. It is used to treat cancer cells that remain after surgery (that would otherwise grow back), but is also used to treat the cancer itself (where surgery has not been done). Chemotherapy may be added as well. However, the use of radiotherapy is complicated because of the closeness to critical areas, (eg the eyes and brain) which can be damaged by radiotherapy. This may sometimes cause serious long-term side effects including eye pain, loss of vision, problems with thinking or memory, epilepsy, sinus inflammation or blockage, reduced hormone levels and difficulties hearing and smelling. Intensity-modulated radiotherapy (IMRT) is the current standard treatment. It is a way of targeting a tumour in the body more precisely and has helped to improve cure rates and reduce side effects compared with older techniques. Proton beam therapy (PBT) is a newer form of radiotherapy which may further improve delivery of radiation. This trial will compare cure rates of PBT to the standard IMRT treatment. It will also gather information on side effects of each, to determine whether one treatment causes less damage than the other. Participants have a 50:50 chance of receiving IMRT at a local hospital, or PBT at one of the specialist UK proton centres (Manchester or London). Delivery of radiotherapy will happen over 6-7 weeks. All other treatment decisions and options will be the same whether taking part in the study or not. After completing the radiotherapy participants will attend follow-up clinical appointments for up to 5 years (which match normal care) at set times so that any side-effects can be recorded. |
|
Renal
|
Specialty: Renal |
PI: Dr Natalie Charnley |
|
CPMS No: 69744 |
Estimated Opening: 01/04/2026 |
|
Description: This is a Phase 3, randomized, placebo-controlled, double-blind, 2-arm, global, multicenter study to evaluate the PFS of casdatifan versus placebo when each is given in combination with cabozantinib in patients with confirmed advanced or metastatic ccRCC following progression on prior anti-PD-1 immunotherapy. |
|
Upper Gastrointestinal
|
Specialty: Upper Gastrointestinal |
PI: Dr Catherine Mitchell |
|
CPMS No: 58475 |
Estimated Opening: 01/04/2026 |
|
Description: Although the optimal treatment strategy in oesophageal (food pipe) cancer has been the subject of research for several decades, overall outcomes are very poor, with a 5-year survival of 15%. In the UK there are 9100 new cases of oesophago-gastric cancer diagnosed and approximately 7925 deaths every year (Cancer Research UK Oct 2019). Oesophageal cancer is a strategic priority for CRUK and a serious health problem world-wide. Pre-surgery treatment consists of chemotherapy or chemoradiation, but the optimal treatment is unknown. Over 60% of patients experience severe side-effects from their treatment and this impacts their outcomes. Proton beam therapy is a new radiotherapy treatment; there are currently only 2 centres in England with Proton beam therapy machines. Proton beam therapy may help to reduce side-effects and is an important avenue of research. This trial has been funded by CRUK. This study aims to investigate if Proton beam therapy and chemotherapy given before surgery for oesophageal cancer significantly reduces the risk of severe toxicity and prevents delay of post-operative immunotherapy when compared with standard photon radiotherapy. This is a phase II, randomised controlled trial. Patients over 16 years old with resectable oesophageal cancer will be randomised 1:1 into the experimental arm (Proton beam therapy, chemotherapy + surgery) and control arm (photon radiotherapy, chemotherapy + surgery). Patients suitable for immunotherapy will then receive up to 12 months of treatment as per standard of care. This UK trial will recruit patients from 15 NHS sites; all patients randomised to receive Proton beam therapy will be treated at either UCLH/Christie. Patients will receive treatment for 5 weeks before surgery, and for up to 1 year after surgery. Patients will be followed up at NHS sites for up to 1 year, and then survival data will be collected from NHS Digital for a further 2 years. |
|